MITHRIL
Venture capitalSan Francisco Β· 1 people tracked
Find your way into MITHRIL
Fund manager profile
MITHRIL is a venture fund manager based in San Francisco. SEC filings show 1 venture fund on record, most recently MITHRIL II LP ($740.3M offering) filed January 2017.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
Team Β· 1 people
from public directoriesWhat they invest in
from 6 of 7 portfolio companiesBiotech Γ3Healthtech Γ3Medical Devices Γ2Robotics Γ2B2B Marketplaces Γ1Cloud Computing Γ1Deep Tech Γ1Hardware Γ1
HQs:United StatesΓ5
Investments Β· 7 tracked
founders shown can be your intro pathBy year:2021 Β· 12019 Β· 12014 Β· 13 dated
Invivyd develops monoclonal antibody therapies to prevent and treat serious viral infections, beginning with COVID-19 and expanding to respiratory syncytial virus and measles.
BiotechWaltham, US
Tillman U. Gerngross(Executive Officer, Director)Lynn Connolly(Executive Officer)Eric Kimble(Executive Officer)inHalley Gilbert(Executive Officer)Rebecca Dabora(Executive Officer)inEllie Hershberger(Executive Officer)
Co-investorsFidelity InvestmentsForesite CapitalGV (Google Ventures)Mithril Capital ManagementOrbiMedPolaris Partners+3 more
Fractyl develops therapies for obesity and type 2 diabetes, focusing on non-drug-based approaches rooted in understanding metabolic disease mechanisms.
BiotechHealthtechMedical DevicesLexington, US
HARITH RAJAGOPALAN(Executive Officer, Director)inJAY CAPLAN(Executive Officer, Director)inJay Caplan(Executive Officer, Director)inHarith Rajagopalan(Executive Officer, Director)inLISA DAVIDSON(Executive Officer)inDiane Marcou(Executive Officer)in
Co-investorsBessemer Venture PartnersCatalio Capital Management, LPEmergent Medical Partners, LLPDomain AssociatesGeneral CatalystMithril Capital Management+2 more
.png)
Invivyd develops monoclonal antibody medicines for the prevention and treatment of serious viral infectious diseases, starting with COVID-19 and other high-need indications.
BiotechHealthtech
Co-investorsBain Capital Life SciencesForesite CapitalMRL Ventures FundPremji InvestGV (Google Ventures)Mithril Capital Management+2 more
Neocis develops Yomi, a robotic surgical platform that assists clinicians during dental implant surgery with planning, surgical, and restorative software features.
HealthtechMedical DevicesRoboticsMiami, US
Alon Mozes(CEO & Co-Founder)inJuan Salcedo(Engineering Fellow & Co-Founder)inJUAN SALCEDO(Executive Officer)inALON MOZES(Executive Officer, Director)inDennis Moses(Chief Technical Officer)inAndres Carrillo(VP of Product)in
Co-investorsIntuitive VenturesNorwest Venture PartnersVivo CapitalB Capital GroupMirae Asset Venture InvestmentMithril Capital Management+1 more
.jpeg){kind=logo}
Fusion Engineering develops flight controller hardware and software for multirotor drones, focused on safety and reliability to enable certified drone flights over urban areas and in offshore conditions.
Deep TechHardwareRobotics
Co-investorsGENIUS NYY Combinator
AppDirect operates a B2B commerce platform for selling, buying, and managing recurring technology services, letting businesses launch white-labeled or internal IT marketplaces.
B2B MarketplacesCloud ComputingSaaSSan Francisco, US
Daniel Saks(Executive Officer, Director)inNicolas Desmarais(Executive Officer, Director)Audrey Garfield(Executive Officer)Paul Desmarais Jr.(Director)Robert Fetherstonhaugh(Director)
BoardChris Arsenault(Director)in
Co-investorsFoundryKensington Capital Partners LimitedInovia CapitalJ.P. Morgan Asset ManagementMithril Capital ManagementStarVest Partners
Tukwila, US
Jason Andrews(Executive Officer, Director, Promoter)inMarian Joh(Director, Promoter)inCurt Blake(Director)inIndra Hornsby(Executive Officer)inTom Neary(Executive Officer)in
BoardGabriel Kompkoff(Director)
Co-investorsMithril Capital ManagementRazor's Edge Ventures
Exits Β· 3
3 IPOsAdagio TherapeuticsNASDAQ: IVVDFractylNASDAQ: GUTSInvivydNASDAQ: IVVD
Portfolio news
latest coverage across their companiesInvivyd Β· investors.invivyd.com Β· Sep 1, 2026
Fusion Β· techtimes.com Β· Jul 31, 2026
Fractyl Β· investing.com Β· Jul 15, 2026
IPO stake values Β· per SEC filings Β· 3
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Adagio Therapeutics | 8.5% | $17.00 | Aug 2021 | $157.2M |
| Invivyd | 8.5% | $17.00 | Aug 2021 | $157.2M |
| Fractyl | 12.8% | $15.00 | Feb 2024 | $91.2M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned Γ the initial public offering price, as disclosed β a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has MITHRIL made?
- MITHRIL has 7 tracked investments, 3 of which have exited.
- Where is MITHRIL located?
- MITHRIL is headquartered in San Francisco, US.
Media Β· Podcasts & interviews
featuring the teamBuilding to Last - Ajay Royan, Mithril
Beyond Innovation TV Β· Ajay Royan
Beyond Innovation #11: Silicon Valley Shift with Mithril Capital's Ajay Royan
Beyond Innovation TV Β· Ajay Royan
Building to Last - Ajay Royan, Mithril | What does it take to be a successful #VentureCapital firm? "You have to be constructive, you cannot become cynical. At the same time you have to be very... | By Globalive Media
Ajay Royan Β· facebook.com